22 November 2022 - Shanghai Junshi Biosciences announced today that the supplemental application for additional indications of adalimumab injection (UBP1211) for the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohn’s disease in children has been approved by the NMPA.

UBP1211 is jointly developed by Junshi Biosciences and Mabwell (Shanghai) Bioscience. In March 2022, it's indications including rheumatoid arthritis, ankylosing spondylitis and psoriasis were approved by the NMPA.

Read Junshi Biosciences press release